Stay updated with breaking news from Markus Magerl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the
Pharvaris N.V. announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network Urticaria Centers of Reference and Excellence Conference, being held...
ZUG, Switzerland, Nov. 30, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks, today...
ZUG, Switzerland, Sept. 06, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today...
ZUG, Switzerland, Aug. 23, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today...